The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Descriptive study results for low-dose cyclophosphamide with bortezomib and low-dose dexamethasone in RRMM

Sep 27, 2017

A phase III studypublished in Annals of Hematologyassessed the effect of adding continuous low-dose cyclophosphamide to the backbone regimen of bortezomib and low-dose dexamethasone, in patients with primary Refractory or Relapsed Multiple Myeloma (RRMM).

The open-label, randomized and controlled study was terminated early however, due to insufficient sample size. Descriptive results were published by Martin Kropff, Department of Haematology at Medizinische Klinik III, Osnabrück, Germany, and colleagues.

Key Findings

  • Patients (pts) n = 90
  • Median follow-up = 24 months
  • Pts randomized 1:1 to receive eight 3-week cycles of bortezomib 1.3 mg/m 2and dexamethasone 20 mg (VD; n = 43) alone, or in combination with cyclophosphamide at 50 mg (VCD; n = 47)
  • Median Time to Progression (TTP): VD vsVCD = 6 vs9.9 months ( P= 0.192)
  • Disease Progression: VD vsVCD = 65% vs72% (HR = 0.71, 95% CI; 0.43–1.19, P= 0.196)
  • Overall Response Rate (ORR): VD vsVCD = 32 pts (74%) vs33 pts (70%)
  • Median OS: VD vsVCD = not determined vs41 months


  • Grade ≥3 peripheral neuropathy: VD vsVCD = 4% vs15%
  • Infection rate: VD vsVCD = 52% vs64%
  • Most common Adverse Events (AEs): thrombocytopenia (38%), peripheral neuropathy (35%), fatigue (34%), diarrhea (30%), constipation (25%) and anemia (19%)
  • Death: VD vsVCD = 13 pts (30%) vs18 pts (38%) (HR = 0.85, 95% CI = 0.41–1.73, P= 0.645)


The study results for median TTP, ORR and disease progression did not indicate an additional benefit for the use of VCD compared with VD, for the treatment of primary RRMM patients. However, since the proposed sample size was not reached and the study was terminated early, further trials may be required to fully assess the clinical benefit of VCD. The safety profiles of both therapies were relatively similar with VCD showing slightly higher grade ≥3 peripheral neuropathy. The authors commented that the lack of benefit may be due to the use of a low-dose of cyclophosphamide and therefore investigating higher dosing schedules in a VCD combo may be of interest. 

  1. Kropff M. et al.Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. Annals of Hematology. 2017 Sep 14. DOI: 10.1007/s00277-017-3065-z. [Epub ahead of print]